Outcomes

The evidence for testosterone undecanoate outcomes comes primarily from clinical studies examining various patient populations, though specific quantitative results are limited in the available literature summaries.

Hormonal and Biochemical Outcomes

Studies have documented measurable changes in testosterone levels following oral testosterone undecanoate administration. Research has identified specific urinary proteomic signatures associated with exogenous testosterone exposure, suggesting reliable biomarker detection methods for monitoring treatment effects.

Growth and Development Outcomes

In pediatric populations, testosterone undecanoate has shown benefits for boys with constitutional delay of growth and puberty. A systematic review and meta-analysis found evidence for growth promotion, though the strength of this evidence requires further evaluation given the exploratory nature of the analysis. Low-dose testosterone treatment specifically improved wellbeing and emotional state in boys with self-limited delayed puberty, representing measurable psychosocial outcomes.

Muscle and Bone Health Outcomes

Several studies have examined testosterone undecanoate's effects on musculoskeletal health. In men with cirrhosis, testosterone addition to nutrition and exercise programs has been studied for muscle mass improvements, though specific quantitative results are not detailed in available summaries. A randomized controlled trial investigated testosterone-augmented multimodal exercise interventions in spinal cord injury patients, focusing on bone and muscle health outcomes.

Safety and Adverse Events

The literature reports potential serious adverse events, including a case of cerebral venous sinus thrombosis associated with testosterone use in gender-affirming hormone therapy. This represents a rare but significant safety consideration.

Mortality Outcomes

Research has examined the association between age and mortality in men with adult-onset testosterone deficiency receiving testosterone therapy, suggesting potential mortality-related benefits, though the specific nature and magnitude of these effects require further clarification.

Evidence Limitations: While multiple completed Phase 2 and Phase 3 clinical trials are referenced, the available evidence summaries do not provide specific quantitative outcome measures, effect sizes, or statistical significance data. The strength of evidence varies across indications, with some outcomes based on single studies or case reports.

This information is for educational purposes only and should not replace consultation with a healthcare provider for individual medical decisions.

Testosterone Undecanoate

Member access required